Build my stack
Home · Guides · Are peptides legal? · Alaska

Are Peptides Legal in Alaska? (2026)

Not legal advice. This page summarises public statutes, board statements and enforcement records for Alaska as of 28 September 2026, for general information. It is not a legal opinion. Laws change; check the linked sources or a licensed Alaska attorney before relying on anything here. Compounds are discussed in a research context only.
Short answer. There is no Alaska statute that bans buying or possessing research peptides as a category. Federal law does the regulating: selling an unapproved peptide for human use is a federal violation by the seller, and human growth hormone has its own federal statute. The Bureau found no peptide that Alaska has scheduled or banned on its own. Verified against the sources listed at the bottom on 28 September 2026. Not legal advice.

Alaska at a glance

State controlled-substances law
Alaska Stat. § 11.71.010 et seq.; schedules IA to VIA at AS 11.71.140 to 11.71.190 (codes.findlaw.com)
Human growth hormone under state law
Not separately scheduled; the federal statute 21 U.S.C. § 333(e) applies (AS 11.71.160 (Schedule IIIA) and AS 11.71.180 (Schedule VA, 27 named anabolic steroids)) (codes.findlaw.com)
Research peptides scheduled by the state
None found
Board of Pharmacy on compounded GLP-1s
No statement located
Medical board on peptide prescribing
No statement located
GLP-1 by telehealth
No Alaska-specific GLP-1 or in-person examination restriction was found. Physician telemedicine is governed by AS 08.64.364, and Alaska-licensed prescribers may prescribe approved drugs such as semaglutide by telehealth under the same prescription rules as in person. The statute text itself could not be opened during this check. (akleg.gov)
State-level enforcement, 2023 to 2026
None found
Last verified
28 September 2026, confidence medium

The federal rules that apply in Alaska, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in Alaska:

  • Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
  • Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including Alaska. The PCAC vote page has every tally.
  • GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What Alaska law adds

Alaska's controlled-substances law (Alaska Stat. § 11.71.010 et seq.; schedules IA to VIA at AS 11.71.140 to 11.71.190) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (codes.findlaw.com)

The Bureau found no research peptide (BPC-157, TB-500, ipamorelin, sermorelin, semaglutide, tirzepatide, retatrutide or the others covered on this site) on Alaska's schedules or in a Alaska-specific ban as of September 2026. That is the position in most states.

Human growth hormone

Human growth hormone is not listed in Alaska's Schedule IIIA or Schedule VA, which names 27 anabolic steroids; only the federal HGH statute applies. (AS 11.71.160 (Schedule IIIA) and AS 11.71.180 (Schedule VA, 27 named anabolic steroids)) (codes.findlaw.com)

Compounded semaglutide and tirzepatide

No Alaska Board of Pharmacy statement specific to compounded GLP-1 drugs was located. Licensed Alaska pharmacies follow the federal 503A and 503B rules, under which the shortage exception for semaglutide and tirzepatide has ended.

Clinics, medspas and prescribers

No Alaska medical board guidance specific to peptide therapy was located. A Alaska prescriber who administers BPC-157 or another unapproved peptide is exposed under the state's medical practice act and, since the FDA's 2026 letters, under federal law; the July 2026 advisory vote has not changed that yet.

Buying, possessing and using research peptides in Alaska

No Alaska provision specific to research peptides was found; they are absent from AS 11.71.160 and 11.71.180, so the federal rules apply. (codes.findlaw.com)

Ordering from a vendor in another state. Almost every research-peptide order into Alaska is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. No Alaska-specific GLP-1 or in-person examination restriction was found. Physician telemedicine is governed by AS 08.64.364, and Alaska-licensed prescribers may prescribe approved drugs such as semaglutide by telehealth under the same prescription rules as in person. The statute text itself could not be opened during this check. (akleg.gov) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a Alaska law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes

Enforcement in Alaska

The Bureau found no Alaska-level action against a peptide seller, clinic or compounded-GLP-1 seller between 2023 and September 2026. Federal actions apply regardless of state; the enforcement tracker lists them.

Editor's note. No Alaska pharmacy board or medical board statement on compounded GLP-1s or peptides was found. The telehealth statute text should be confirmed against akleg.gov.

Frequently asked questions

Is BPC-157 legal in Alaska?

Alaska has not scheduled BPC-157, so possessing it is not a Alaska offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in Alaska?

No Alaska-specific GLP-1 or in-person examination restriction was found. Physician telemedicine is governed by AS 08.64.364, and Alaska-licensed prescribers may prescribe approved drugs such as semaglutide by telehealth under the same prescription rules as in person. The statute text itself could not be opened during this check. Compounded versions are no longer covered by the FDA's shortage exception, and the FDA has proposed keeping semaglutide and tirzepatide off the 503B bulks list, so expect availability of compounded product to keep shrinking.

Is HGH legal in Alaska?

Only with a valid prescription for an approved use. Alaska does not schedule it separately, but federal law, 21 U.S.C. section 333(e), makes distribution or possession for any non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

Every Alaska fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.